Javascript was detected to be disabled. Javascript is required for some functions on this website.

The Institute for Innovation & Valuation in Health Care, InnoValHC, is an independent not-for-profit research organization. It was established by scientists with medical, health economic, and econometric backgrounds, as well as hands-on management experience, to analyse health economic and treatment strategies (see Profile). Learn more about the institute's Purpose and Projects.

News

Recent Scientific Publication on the Budget Impact of Drugs for Rare and Ultrarare Diseases

Now available for download:
A systematic review on the "Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases”.

Read more …

Recent Scientific Presentations at the HTAi 2017 Annual Meeting in Rome / Italy, June 17 – 21, 2017

Now available for download:

Research presentations on "An Update on the Economic Value of a Statistical Life Year in Europe" and "Is NICE in the UK more Innovation-Friendly than IQWiG/GBA in Germany?" at the 2017 HTAi Annual Meeting in Rome / Italy, June 17-21, 2017.

Read more …

Health Technology Assessment (HTA) for Medical Products – How to Cope with the Increasing Regulatory Burden?

Now online available: Presentation on "Health Technology Assessment (HTA) for Medical Products - How to Cope with the Increasing Regulatory Burden?" at the MedTech Dialogue Meeting in Mannheim / Germany, on March 23, 2017.

Read more …

Common Principles for Value Determination and Assessment

Now online available: Invited panel contribution on "Common Principles for Value Determination and Assessment" at the "Second EURORDIS Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies" in Brussels / Belgium, February 22/23, 2017.

Read more …

Interventions for Ultra-Rare Disorders (URDs): How to Assess “Value for Money”?

Now available for download:

The “URD Consensus” documented as a peer-reviewed publication in the Journal of Market Access and Health Policy.

Read more …